No Data
No Data
Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Held Back By Insufficient Growth Even After Shares Climb 33%
Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) shares have continued their recent momentum with a 33% gain in the last month alone. But the gains over the last month weren't enough to make
Shanghai Shyndec Pharmaceutical (SHSE:600420) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Year, but the Stock Lifts 5.0% This Past Week
While not a mind-blowing move, it is good to see that the Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) share price has gained 26% in the last three months. But that doesn't change the fa
Sinopharm Hyundai (600420.SH) announced first-quarter results, net profit of 331 million yuan, up 84.83% year-on-year
According to Zhitong Finance App News, Sinopharm Hyundai (600420.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 3.123 billion yuan, a year-on-year decrease of 8.6%; net profit attributable to shareholders of listed companies was 331 million yuan, an increase of 84.83% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 326 million yuan, an increase of 91.04% year on year; basic earnings per share were 0.2470 yuan.
Sinopharm Hyundai (600420.SH): The company's current hypoglycemic drugs include engagliflozin tablets
Gelonghui, April 24 | Sinopharm Hyundai (600420.SH) said on the investor interactive platform that the company currently has glucose-lowering drugs such as engliflozin tablets, as well as the active ingredients acarbose and voglibose. None of the above drugs currently have any weight-loss-related indications.
Sinopharm Hyundai (600420.SH): Injectable ceftriaxone passes consistent evaluation of generic drug quality and efficacy
Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Weiqida Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets
Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Rongsheng Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its empaglif
No Data